JP5662166B2 - 胃癌の診断、予後診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物 - Google Patents
胃癌の診断、予後診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物 Download PDFInfo
- Publication number
- JP5662166B2 JP5662166B2 JP2010548899A JP2010548899A JP5662166B2 JP 5662166 B2 JP5662166 B2 JP 5662166B2 JP 2010548899 A JP2010548899 A JP 2010548899A JP 2010548899 A JP2010548899 A JP 2010548899A JP 5662166 B2 JP5662166 B2 JP 5662166B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- expression
- marker
- cells
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 158
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims description 111
- 206010017758 gastric cancer Diseases 0.000 title claims description 111
- 201000011549 stomach cancer Diseases 0.000 title claims description 111
- 238000004393 prognosis Methods 0.000 title claims description 4
- 108700011259 MicroRNAs Proteins 0.000 title description 224
- 239000000203 mixture Substances 0.000 title description 43
- 238000011282 treatment Methods 0.000 title description 29
- 238000003745 diagnosis Methods 0.000 title description 2
- 230000014509 gene expression Effects 0.000 claims description 327
- 239000003550 marker Substances 0.000 claims description 211
- 206010028980 Neoplasm Diseases 0.000 claims description 89
- 108091085564 miR-25 stem-loop Proteins 0.000 claims description 87
- 108091080167 miR-25-1 stem-loop Proteins 0.000 claims description 87
- 108091083056 miR-25-2 stem-loop Proteins 0.000 claims description 87
- 239000000523 sample Substances 0.000 claims description 87
- 239000000090 biomarker Substances 0.000 claims description 61
- 238000012360 testing method Methods 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 38
- 108091070501 miRNA Proteins 0.000 claims description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 239000013068 control sample Substances 0.000 claims description 12
- 230000000692 anti-sense effect Effects 0.000 claims description 11
- 108091045790 miR-106b stem-loop Proteins 0.000 claims description 8
- 108091032902 miR-93 stem-loop Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 description 283
- 108090000623 proteins and genes Proteins 0.000 description 242
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 217
- 201000010099 disease Diseases 0.000 description 123
- 102000004169 proteins and genes Human genes 0.000 description 117
- 208000035475 disorder Diseases 0.000 description 94
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 83
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 83
- 239000002679 microRNA Substances 0.000 description 77
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 68
- 230000000694 effects Effects 0.000 description 67
- 150000001875 compounds Chemical class 0.000 description 66
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 65
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 65
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 65
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 65
- 102000039446 nucleic acids Human genes 0.000 description 62
- 108020004707 nucleic acids Proteins 0.000 description 62
- 150000007523 nucleic acids Chemical class 0.000 description 62
- 108091034117 Oligonucleotide Proteins 0.000 description 48
- 239000003795 chemical substances by application Substances 0.000 description 45
- 239000002243 precursor Substances 0.000 description 43
- 210000001519 tissue Anatomy 0.000 description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
- 230000000295 complement effect Effects 0.000 description 39
- 230000006907 apoptotic process Effects 0.000 description 36
- 101150023098 Mcm7 gene Proteins 0.000 description 33
- 238000011529 RT qPCR Methods 0.000 description 33
- 230000002018 overexpression Effects 0.000 description 30
- 239000003814 drug Substances 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 28
- 238000012230 antisense oligonucleotides Methods 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- 239000000074 antisense oligonucleotide Substances 0.000 description 25
- 230000001105 regulatory effect Effects 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 24
- 230000025084 cell cycle arrest Effects 0.000 description 24
- 230000004044 response Effects 0.000 description 24
- 238000001890 transfection Methods 0.000 description 24
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 230000001419 dependent effect Effects 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000012010 growth Effects 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 19
- 238000011161 development Methods 0.000 description 19
- 230000018109 developmental process Effects 0.000 description 19
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 206010061968 Gastric neoplasm Diseases 0.000 description 17
- 238000010171 animal model Methods 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 208000007882 Gastritis Diseases 0.000 description 16
- 230000008859 change Effects 0.000 description 16
- 208000023652 chronic gastritis Diseases 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 230000014616 translation Effects 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 230000022131 cell cycle Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 108091091751 miR-17 stem-loop Proteins 0.000 description 14
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 14
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 14
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 13
- 239000012472 biological sample Substances 0.000 description 13
- 230000003828 downregulation Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 238000010361 transduction Methods 0.000 description 13
- 230000026683 transduction Effects 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 230000009368 gene silencing by RNA Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 108091030071 RNAI Proteins 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 238000002493 microarray Methods 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000010609 cell counting kit-8 assay Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 230000003827 upregulation Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108090000672 Annexin A5 Proteins 0.000 description 9
- 102000004121 Annexin A5 Human genes 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 108010087230 Sincalide Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000001124 posttranscriptional effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 231100000747 viability assay Toxicity 0.000 description 8
- 238000003026 viability measurement method Methods 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 210000001156 gastric mucosa Anatomy 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 108091059456 miR-92-1 stem-loop Proteins 0.000 description 6
- 108091084336 miR-92-2 stem-loop Proteins 0.000 description 6
- 230000002974 pharmacogenomic effect Effects 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 230000005748 tumor development Effects 0.000 description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 description 5
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 description 5
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 description 5
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 5
- 108091030146 MiRBase Proteins 0.000 description 5
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 5
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 101000992394 Homo sapiens Oxysterol-binding protein-related protein 5 Proteins 0.000 description 4
- 108091062140 Mir-223 Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108090001145 Nuclear Receptor Coactivator 3 Proteins 0.000 description 4
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102100032148 Oxysterol-binding protein-related protein 5 Human genes 0.000 description 4
- 108010052090 Renilla Luciferases Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000012707 chemical precursor Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108091064157 miR-106a stem-loop Proteins 0.000 description 4
- 108091062762 miR-21 stem-loop Proteins 0.000 description 4
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 4
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 4
- -1 miR-93 Proteins 0.000 description 4
- 108091007426 microRNA precursor Proteins 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 108091007428 primary miRNA Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100032537 Calpain-2 catalytic subunit Human genes 0.000 description 3
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 206010067671 Disease complication Diseases 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 101000867692 Homo sapiens Calpain-2 catalytic subunit Proteins 0.000 description 3
- 101000596404 Homo sapiens Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003150 biochemical marker Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000010293 colony formation assay Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108091049679 miR-20a stem-loop Proteins 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229950006344 nocodazole Drugs 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000006461 physiological response Effects 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 230000022983 regulation of cell cycle Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- 206010007269 Carcinogenicity Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000008051 G1/S transition checkpoint Effects 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 2
- 101000610204 Homo sapiens Poly(A) polymerase alpha Proteins 0.000 description 2
- 108091033773 MiR-155 Proteins 0.000 description 2
- 108091028049 Mir-221 microRNA Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102100040155 Poly(A) polymerase alpha Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000005773 cancer-related death Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 231100000260 carcinogenicity Toxicity 0.000 description 2
- 230000007670 carcinogenicity Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108091043222 miR-181b stem-loop Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010023936 Cofilin 2 Proteins 0.000 description 1
- 102000011424 Cofilin 2 Human genes 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 230000004707 G1/S transition Effects 0.000 description 1
- 102100035964 Gastrokine-2 Human genes 0.000 description 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 description 1
- 102100039544 Homeobox protein Hox-D10 Human genes 0.000 description 1
- 102100033798 Homeobox protein aristaless-like 4 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000962573 Homo sapiens Homeobox protein Hox-D10 Proteins 0.000 description 1
- 101000779608 Homo sapiens Homeobox protein aristaless-like 4 Proteins 0.000 description 1
- 101000994432 Homo sapiens Josephin-1 Proteins 0.000 description 1
- 101001006886 Homo sapiens Krueppel-like factor 12 Proteins 0.000 description 1
- 101001129705 Homo sapiens PH domain leucine-rich repeat-containing protein phosphatase 2 Proteins 0.000 description 1
- 101000583178 Homo sapiens Pleckstrin homology domain-containing family M member 1 Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 101001047637 Homo sapiens Serine/threonine-protein kinase LATS2 Proteins 0.000 description 1
- 101001098093 Homo sapiens Transcriptional repressor p66-beta Proteins 0.000 description 1
- 101000837574 Homo sapiens Ubiquitin-conjugating enzyme E2 W Proteins 0.000 description 1
- 101000964479 Homo sapiens Zinc finger and BTB domain-containing protein 18 Proteins 0.000 description 1
- 101000781856 Homo sapiens Zinc finger protein 512B Proteins 0.000 description 1
- 101000931371 Homo sapiens Zinc finger protein ZFPM2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102100032732 Josephin-1 Human genes 0.000 description 1
- 102100027792 Krueppel-like factor 12 Human genes 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 108091007773 MIR100 Proteins 0.000 description 1
- 108091007774 MIR107 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 108091033433 MiR-191 Proteins 0.000 description 1
- 108091028141 MiR-203 Proteins 0.000 description 1
- 108091028108 MiR-212 Proteins 0.000 description 1
- 108091026807 MiR-214 Proteins 0.000 description 1
- 108091062154 Mir-205 Proteins 0.000 description 1
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 description 1
- 108091060302 Mir-320 Proteins 0.000 description 1
- 108091027559 Mir-96 microRNA Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101150079937 NEUROD1 gene Proteins 0.000 description 1
- 108700020297 NeuroD Proteins 0.000 description 1
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100031136 PH domain leucine-rich repeat-containing protein phosphatase 2 Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100030349 Pleckstrin homology domain-containing family M member 1 Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100024043 Serine/threonine-protein kinase LATS2 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100037556 Transcriptional repressor p66-beta Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100028700 Ubiquitin-conjugating enzyme E2 W Human genes 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 102100040762 Zinc finger and BTB domain-containing protein 18 Human genes 0.000 description 1
- 102100036647 Zinc finger protein 512B Human genes 0.000 description 1
- 102100020996 Zinc finger protein ZFPM2 Human genes 0.000 description 1
- FPKBIYKAYFGTKG-UHFFFAOYSA-N [5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl] [3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methyl hydrogen phosphate Chemical compound Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O FPKBIYKAYFGTKG-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000009950 gastric cancer growth Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091037473 miR-103 stem-loop Proteins 0.000 description 1
- 108091084090 miR-106 stem-loop Proteins 0.000 description 1
- 108091050539 miR-107 stem-loop Proteins 0.000 description 1
- 108091064399 miR-10b stem-loop Proteins 0.000 description 1
- 108091091360 miR-125b stem-loop Proteins 0.000 description 1
- 108091051410 miR-130 stem-loop Proteins 0.000 description 1
- 108091050366 miR-130-1 stem-loop Proteins 0.000 description 1
- 108091054878 miR-130-2 stem-loop Proteins 0.000 description 1
- 108091047467 miR-136 stem-loop Proteins 0.000 description 1
- 108091041042 miR-18 stem-loop Proteins 0.000 description 1
- 108091055042 miR-181 stem-loop Proteins 0.000 description 1
- 108091062221 miR-18a stem-loop Proteins 0.000 description 1
- 108091074848 miR-19 stem-loop Proteins 0.000 description 1
- 108091087148 miR-20 stem-loop Proteins 0.000 description 1
- 108091066984 miR-20-1 stem-loop Proteins 0.000 description 1
- 108091076199 miR-20-2 stem-loop Proteins 0.000 description 1
- 108091045665 miR-202 stem-loop Proteins 0.000 description 1
- 108091053935 miR-212 stem-loop Proteins 0.000 description 1
- 108091028397 miR-212-1 stem-loop Proteins 0.000 description 1
- 108091028945 miR-212-2 stem-loop Proteins 0.000 description 1
- 108091040176 miR-218 stem-loop Proteins 0.000 description 1
- 108091061917 miR-221 stem-loop Proteins 0.000 description 1
- 108091063489 miR-221-1 stem-loop Proteins 0.000 description 1
- 108091055391 miR-221-2 stem-loop Proteins 0.000 description 1
- 108091031076 miR-221-3 stem-loop Proteins 0.000 description 1
- 108091080321 miR-222 stem-loop Proteins 0.000 description 1
- 108091083275 miR-26b stem-loop Proteins 0.000 description 1
- 108091072810 miR-294 stem-loop Proteins 0.000 description 1
- 108091076076 miR-295 stem-loop Proteins 0.000 description 1
- 108091065159 miR-339 stem-loop Proteins 0.000 description 1
- 108091044951 miR-339-2 stem-loop Proteins 0.000 description 1
- 108091055145 miR-342 stem-loop Proteins 0.000 description 1
- 108091062109 miR-372 stem-loop Proteins 0.000 description 1
- 108091043953 miR-373 stem-loop Proteins 0.000 description 1
- 108091086713 miR-96 stem-loop Proteins 0.000 description 1
- 108091070961 miR-96-3 stem-loop Proteins 0.000 description 1
- 108091053257 miR-99b stem-loop Proteins 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 208000036506 well differentiated low or intermediate grade gastric neuroendocrine tumor Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/205—Aptamer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6744508P | 2008-02-28 | 2008-02-28 | |
| US61/067,445 | 2008-02-28 | ||
| PCT/US2009/035458 WO2009108853A1 (en) | 2008-02-28 | 2009-02-27 | MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516032A JP2011516032A (ja) | 2011-05-26 |
| JP2011516032A5 JP2011516032A5 (https=) | 2013-03-21 |
| JP5662166B2 true JP5662166B2 (ja) | 2015-01-28 |
Family
ID=41016479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548899A Expired - Fee Related JP5662166B2 (ja) | 2008-02-28 | 2009-02-27 | 胃癌の診断、予後診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110034538A1 (https=) |
| EP (2) | EP2257647B1 (https=) |
| JP (1) | JP5662166B2 (https=) |
| CN (1) | CN102007223B (https=) |
| AU (1) | AU2009219190A1 (https=) |
| CA (1) | CA2716906A1 (https=) |
| WO (1) | WO2009108853A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5489459B2 (ja) | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
| CA2845251A1 (en) | 2005-09-12 | 2007-03-22 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof |
| JP5490413B2 (ja) | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| EP2487258B1 (en) | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer |
| CN102943108B (zh) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
| ES2446362T3 (es) | 2006-03-20 | 2014-03-07 | The Ohio State University Research Foundation | Huellas de microARN durante megacariocipoyesis humana |
| CA2657030A1 (en) | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| CN101535505A (zh) | 2006-09-19 | 2009-09-16 | 俄亥俄州立大学研究基金会 | 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达 |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN105256004A (zh) | 2007-01-31 | 2016-01-20 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
| ES2527648T3 (es) | 2007-06-08 | 2015-01-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar el subtipo de carcinoma hepatocelular |
| EP2719773A3 (en) | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
| ES2496172T3 (es) | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| JP2010535473A (ja) | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ｎｃＲＮＡをコードする超保存領域 |
| CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| CN102137927B (zh) | 2007-10-26 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
| ES2433940T3 (es) | 2008-06-11 | 2013-12-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia |
| US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| WO2012010584A1 (en) * | 2010-07-20 | 2012-01-26 | Febit Holding Gmbh | Complex mirna sets as novel biomarkers for gastric cancer |
| JP5931897B2 (ja) | 2010-11-12 | 2016-06-08 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法 |
| CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
| SG182016A1 (en) * | 2010-12-14 | 2012-07-30 | Univ Singapore | Method of detecting resistance to cancer therapy |
| WO2012122239A1 (en) | 2011-03-07 | 2012-09-13 | The Ohio State University | MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER |
| CA2833389C (en) * | 2011-04-18 | 2022-01-11 | Diamir, Llc | Mirna-based universal screening test (ust) |
| US8703425B2 (en) * | 2011-09-12 | 2014-04-22 | The Chinese University Of Hong Kong | Biomarker for gastric cancer |
| GB201117482D0 (en) * | 2011-10-11 | 2011-11-23 | Univ Dundee | Targetiing of miRNA precursors |
| AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
| CA2859430A1 (en) | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| WO2014028762A1 (en) * | 2012-08-15 | 2014-02-20 | University Of Virginia Patent Foundation | Compositions and methods for treating peripheral arterial disease |
| WO2014097875A1 (ja) * | 2012-12-20 | 2014-06-26 | 国立大学法人鳥取大学 | 新規の脱分化誘導方法を用いた多能性幹細胞化 |
| CN106460068B (zh) | 2014-06-16 | 2024-08-23 | 东丽株式会社 | 胃癌的检测试剂盒或装置以及检测方法 |
| CN104013975A (zh) * | 2014-06-16 | 2014-09-03 | 山东大学 | Fbxo31基因及其相关产物在制备胃癌治疗药物中的应用 |
| EP4137586B1 (en) | 2014-08-07 | 2026-04-22 | Agency for Science, Technology and Research | Microrna biomarker for the diagnosis of gastric cancer |
| CN104293923A (zh) * | 2014-09-19 | 2015-01-21 | 浙江大学 | 荧光定量PCR检测组织中miR-100含量的试剂盒及其应用 |
| CN106591428B (zh) * | 2016-09-23 | 2021-06-11 | 宁波大学 | 一种胃癌新型分子标记物hsa_circ_0001017的检测及应用 |
| CN106636334B (zh) * | 2016-10-09 | 2020-07-03 | 山东大学 | microRNA标志物组及其在制备检测胃癌淋巴结转移试剂盒中的应用 |
| CN106755513B (zh) * | 2017-02-08 | 2018-10-19 | 泰山医学院 | 一种胃癌的lncRNA标志物 |
| US11576873B2 (en) | 2017-03-31 | 2023-02-14 | The Curators Of The University Of Missouri | Compositions for the treatment of drug-resistant tumors and methods of use thereof |
| CN107217055B (zh) * | 2017-06-26 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种癌症诊断芯片及其试剂盒 |
| CN107641653B (zh) * | 2017-10-20 | 2021-02-19 | 南方医科大学南方医院 | Macc1-as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用 |
| CN108546757B (zh) * | 2018-03-05 | 2021-09-07 | 上海长海医院 | Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用 |
| KR102100124B1 (ko) * | 2018-08-31 | 2020-05-15 | 한국표준과학연구원 | 질량 분석법을 이용한 생체 분자의 고감도 및 고특이적 검출 방법 |
| SG11202106638UA (en) * | 2018-12-19 | 2021-07-29 | Agency Science Tech & Res | Method of diagnosing gastric cancers using micrornas |
| CN117683885A (zh) * | 2019-04-30 | 2024-03-12 | 觅瑞实验室私人有限公司 | 一种检测胃癌的miRNA标志物组合及试剂盒 |
| CN111471764B (zh) * | 2019-12-27 | 2023-09-15 | 陈锦飞 | 一种用于筛查或辅助诊断胃癌的生物标志物组合及其试剂盒和应用 |
| CN111139299B (zh) * | 2020-01-08 | 2021-12-17 | 浙江大学 | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 |
| CN111471683B (zh) * | 2020-04-15 | 2021-09-07 | 湖南省科域生物医药科技有限公司 | miR-93-5p作为诊断和治疗胃癌标志物的应用 |
| CN114678121B (zh) * | 2022-05-30 | 2022-09-09 | 上海芯超生物科技有限公司 | 一种hp球形变诊断模型的构建方法及系统 |
| WO2025245056A1 (en) * | 2024-05-20 | 2025-11-27 | City Of Hope | Gastric cancer rna biomarkers and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1837495A (en) * | 1994-10-13 | 1996-05-06 | Horus Therapeutics, Inc. | Computer assisted methods for diagnosing diseases |
| US6303323B1 (en) * | 1997-10-21 | 2001-10-16 | Cancer Research Campaign Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies |
| US6891031B2 (en) * | 2000-02-18 | 2005-05-10 | The Regents Of The University Of California | Coordinate cytokine regulatory sequences |
| US7455995B2 (en) * | 2001-11-09 | 2008-11-25 | The Ohio State University Research Foundation | BAALC expression as a diagnostic marker for acute leukemia |
| AU2002231843A1 (en) * | 2002-02-12 | 2003-09-04 | Nokia Corporation | Method for controlling data transmission, and data transmission system |
| WO2004071464A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
| US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| US8106180B2 (en) * | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| US20050164252A1 (en) * | 2003-12-04 | 2005-07-28 | Yeung Wah Hin A. | Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell |
| US20060134639A1 (en) * | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
| CN101056991A (zh) * | 2004-04-20 | 2007-10-17 | 基因耐克生物医学制品有限公司 | 检测ncRNA的方法 |
| EP2290071B1 (en) * | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| KR20070058441A (ko) * | 2004-07-01 | 2007-06-08 | 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 면역억제성 엑소솜 |
| JP2008511678A (ja) * | 2004-09-02 | 2008-04-17 | イェール ユニバーシティ | マイクロｒｎａによるオンコジーンの調節 |
| US7642348B2 (en) * | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| US7571055B2 (en) * | 2004-10-13 | 2009-08-04 | Regents Of The University Of Minnesota | Systemic lupus erythematosus |
| CA2857881A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| US8071306B2 (en) * | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| CA2597767A1 (en) * | 2005-02-11 | 2006-08-17 | Wisconsin Alumni Research Foundation | Mir-155 assay |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| JP5490413B2 (ja) * | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| CN102943108B (zh) * | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
| EP2487258B1 (en) * | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer |
| CA2648132C (en) * | 2006-04-03 | 2019-05-28 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| CA2657030A1 (en) * | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| JP2010510964A (ja) * | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路 |
| WO2008073920A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| CA2699418A1 (en) * | 2007-02-27 | 2008-09-04 | Moshe Oren | Composition and methods for modulating cell proliferation and cell death |
| EP2126584B1 (en) * | 2007-03-16 | 2012-12-19 | CovalX AG | Direct mass spectrometric analysis of drug candidates targeting protein complexes |
| WO2009015357A1 (en) * | 2007-07-25 | 2009-01-29 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
| CA2696887C (en) * | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| US20090239818A1 (en) * | 2007-09-07 | 2009-09-24 | Cheng Jin Q | Effective treatment of ovarian cancer using triciribine and related compounds |
| US20100305188A1 (en) * | 2007-10-03 | 2010-12-02 | Kyowa Hakko Kirin Co., Ltd. | Nucleic acid capable of regulating the proliferation of cell |
| EP2623599B1 (en) * | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| EP2217248B1 (en) * | 2007-10-29 | 2016-11-30 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of liver cancer |
| EP2245199B1 (en) * | 2008-02-01 | 2013-11-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| US20110054009A1 (en) * | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders |
| WO2009111375A2 (en) * | 2008-03-01 | 2009-09-11 | Abraxis Bioscience, Llc | Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| EP2268832A2 (en) * | 2008-03-06 | 2011-01-05 | Asuragen, INC. | Microrna markers for recurrence of colorectal cancer |
| WO2009147525A1 (en) * | 2008-06-04 | 2009-12-10 | Karolinska Institutet Innovations Ab | Skin cancer associated micrornas |
| US20100021734A1 (en) * | 2008-07-22 | 2010-01-28 | Covalent Materials Corporation | Ceramic particles and producing method thereof |
| KR101031305B1 (ko) * | 2008-07-23 | 2011-04-29 | 국립암센터 | 마이크로ｒｎａ-21 저해제를 포함하는 방사선 민감성증진용 조성물 |
| US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
| AU2009322907B2 (en) * | 2008-12-05 | 2016-05-05 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer |
-
2009
- 2009-02-27 WO PCT/US2009/035458 patent/WO2009108853A1/en not_active Ceased
- 2009-02-27 CA CA2716906A patent/CA2716906A1/en not_active Abandoned
- 2009-02-27 EP EP09713926.5A patent/EP2257647B1/en not_active Not-in-force
- 2009-02-27 US US12/919,893 patent/US20110034538A1/en not_active Abandoned
- 2009-02-27 JP JP2010548899A patent/JP5662166B2/ja not_active Expired - Fee Related
- 2009-02-27 AU AU2009219190A patent/AU2009219190A1/en not_active Abandoned
- 2009-02-27 CN CN200980112966.1A patent/CN102007223B/zh not_active Expired - Fee Related
- 2009-02-27 EP EP16165519.6A patent/EP3064584A3/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009219190A1 (en) | 2009-09-03 |
| US20110034538A1 (en) | 2011-02-10 |
| EP2257647A1 (en) | 2010-12-08 |
| EP2257647B1 (en) | 2016-09-14 |
| WO2009108853A1 (en) | 2009-09-03 |
| CN102007223A (zh) | 2011-04-06 |
| CA2716906A1 (en) | 2009-09-03 |
| JP2011516032A (ja) | 2011-05-26 |
| EP3064584A2 (en) | 2016-09-07 |
| CN102007223B (zh) | 2014-06-18 |
| EP2257647A4 (en) | 2011-08-03 |
| EP3064584A3 (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5662166B2 (ja) | 胃癌の診断、予後診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物 | |
| JP5976726B2 (ja) | 前立腺関連障害の予後診断及び治療のためのマイクロｒｎａに基づく方法及び組成物 | |
| AU2009322907B2 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
| JP2010535782A (ja) | Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法 | |
| JP2010535473A (ja) | ｎｃＲＮＡをコードする超保存領域 | |
| CN102015027A (zh) | 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途 | |
| JP2020502263A (ja) | Ｎｓｃｌｃを有する患者の処置のための薬剤及び応答を予測するための方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140904 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141014 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141204 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5662166 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |